Company intelligence / Profile preview

Alumis Inc.

South San Francisco, California, United Statesalumis.com ↗

Ownership: Public · ALMS
Development stage: Other

Overview

Alumis’ lead candidate ESK‑001 has shown strong symptomatic improvement in moderate-to-severe plaque psoriasis. It is currently being evaluated in a pivotal Phase 3 trial for this indication with topline data expected first half of 2026. The company’s second asset, A‑005, completed a successful Phase 1 trial and will enter a multiple sclerosis study. Several preclinical programs are also advancing using their precision analytics platform.[6]

Therapeutic areas: NeurologyImmunologyDermatology
Modalities: Small molecules (oral TYK2 inhibitors)Allosteric inhibitors
Industry: Biotech

Drug pipeline

7 assets

envudeucitinib

6 more assets in the full pipeline.

Partnerships

Merger with ACELYRIN to form a late-stage immunology biopharma leader.[1][3]

Financials

Market cap: $757.2M
Total revenue: $24.1M
Enterprise value: $291.3M

Beyond the preview

Go deeper on Alumis Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alumis Inc..